Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$0.00$0.00no prior Q1 2022 on file Net Income-$31.93M-$31.93MN/M vs Q1 2022 EPS Diluted-$0.17-$0.17no prior Q1 2022 on file Operating Income-$31,142,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$31,861,000N/M ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end